Prognostic Value of Preoperative Serum Leucine Aminopeptidases in Hepatocellular Carcinoma Patients Who Underwent Liver Transplantation

References

• Global Burden of Disease Cancer C, Fitzmaurice C, Dicker D, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505–527. doi:10.1001/jamaoncol.2015.073526181261
   PubMed Web of Science ®Google Scholar
• Jelic S, Sotiropoulos GC, Group EGW. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v59–v64. doi:10.1093/annonc/mdq16620555104
   PubMed Web of Science ®Google Scholar
• Verslype C, Rosmorduc O, Rougier P, Group EGW. Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii41–vii48. doi:10.1093/annonc/mds22522997453
   PubMed Web of Science ®Google Scholar
• Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg. 2003;197(5):753–758. doi:10.1016/j.jamcollsurg.2003.07.00314585409
   PubMed Web of Science ®Google Scholar
• Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl. 2000;6(4):429–433. doi:10.1053/jlts.2000.831010915163
   PubMed Web of Science ®Google Scholar
• Kaido T, Morita S, Tanaka S, et al. Long-term outcomes of hepatic resection versus living donor liver transplantation for hepatocellular carcinoma: a propensity score-matching study. Dis Markers. 2015;2015:425926. doi:10.1155/2015/42592625922554
   PubMed Web of Science ®Google Scholar
• Chapman WC, Klintmalm G, Hemming A, et al. Surgical treatment of hepatocellular carcinoma in North America: can hepatic resection still be justified? J Am Coll Surg. 2015;220(4):628–637. doi:10.1016/j.jamcollsurg.2014.12.03025728142
   PubMed Web of Science ®Google Scholar
• Wong RJ, Wantuck J, Valenzuela A, et al. Primary surgical resection versus liver transplantation for transplant-eligible hepatocellular carcinoma patients. Dig Dis Sci. 2014;59(1):183–191. doi:10.1007/s10620-013-2947-824282054
   PubMed Web of Science ®Google Scholar
• Zheng Z, Liang W, Milgrom DP, et al. Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: a meta-analysis of observational studies. Transplantation. 2014;97(2):227–234. doi:10.1097/TP.0b013e3182a8938324142034
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–699. doi:10.1056/NEJM1996031433411048594428
   PubMed Web of Science ®Google Scholar
• Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394–1403. doi:10.1053/jhep.2001.2456311391528
   PubMed Web of Science ®Google Scholar
• Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85(12):1726–1732. doi:10.1097/TP.0b013e31816b67e418580463
   PubMed Web of Science ®Google Scholar
• Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients database. Hepatology. 2009;49(3):832–838. doi:10.1002/hep.2269319152426
   PubMed Web of Science ®Google Scholar
• Hong G, Suh KS, Suh SW, et al. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than milan criteria in living donor liver transplantation. J Hepatol. 2016;64(4):852–859. doi:10.1016/j.jhep.2015.11.03326658686
   PubMed Web of Science ®Google Scholar
• Cheung TT, Ho CL, Lo CM, et al. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of milan criteria: surgeon’s perspective. J Nucl Med. 2013;54(2):192–200. doi:10.2967/jnumed.112.10751623321459
   PubMed Web of Science ®Google Scholar
• Chen CL, Cheng YF, Yu CY, et al. Living donor liver transplantation: the Asian perspective. Transplantation. 2014;97(Suppl 8):S3. doi:10.1097/TP.0000000000000060
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43. doi:10.1016/S1470-2045(08)70284-519058754
   PubMed Web of Science ®Google Scholar
• Fernandez JA, Robles R, Marin C, et al. Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size? Transplant Proc. 2003;35(5):1818–1820. doi:10.1016/S0041-1345(03)00723-112962807
   PubMed Web of Science ®Google Scholar
• Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of milan criteria. Gastroenterology. 2012;143(4):986–94e3; quiz e14–e15. doi:10.1053/j.gastro.2012.05.052
   PubMed Web of Science ®Google Scholar
• Rawlings ND, Barrett AJ. Handbook of Proteolytic Enzymes Introduction: Metallopeptidases and Their Clans. 2nd ed. Elsevier/Academic Press; 2004:231–268.
   Google Scholar
• Matsui M, Fowler JH, Walling LL. Leucine aminopeptidases: diversity in structure and function. Biol Chem. 2006;387(12):1535–1544. doi:10.1515/BC.2006.19117132098
   PubMed Web of Science ®Google Scholar
• Smith EL, Hill RL. The Enzymes: Leucine Aminopeptidase. Vol. 4 Academic Press, Inc; 1960:37–62.
   Google Scholar
• Huang H, Tanaka H, Hammock BD, Morisseau C. Novel and highly sensitive fluorescent assay for leucine aminopeptidases. Anal Biochem. 2009;391(1):11–16. doi:10.1016/j.ab.2009.05.00419433052
   PubMed Web of Science ®Google Scholar
• Phillips RW, Manildi ER. Elevation of leucine aminopeptidase in disseminated malignant disease. Cancer. 1970;26(5):1006–1012. doi:10.1002/1097-0142(197011)26:5<1006::aid-cncr2820260507>3.0.co;2-i5536328
   PubMed Web of Science ®Google Scholar
• Kohno H, Kanda S, Kanno T. Immunoaffinity purification and characterization of leucine aminopeptidase from human liver. J Biol Chem. 1986;261(23):10744–10748. doi:10.1016/S0021-9258(18)67448-43733731
   PubMed Web of Science ®Google Scholar
• Tian S-Y, Chen S-H, Shao B-F, et al. Expression of leucine aminopeptidase 3 (LAP3) correlates with prognosis and malignant development of human hepatocellular carcinoma (HCC). Int J Clin Exp Pathol. 2014;7(7):3752–3762.25120751
   PubMed Web of Science ®Google Scholar
• Abouzied MM, Eltahir HM, Fawzy MA, et al. Estimation of leucine aminopeptidase and 5-nucleotidase increases alpha-fetoprotein sensitivity in human hepatocellular carcinoma cases. Asian Pac J Cancer Prev. 2015;16(3):959–963. doi:10.7314/apjcp.2015.16.3.95925735389
   PubMedGoogle Scholar
• Ren QQ, Fu SJ, Zhao Q, et al. Prognostic value of preoperative peripheral monocyte count in patients with hepatocellular carcinoma after liver transplantation. Tumour Biol. 2016;37(7):8973–8978. doi:10.1007/s13277-015-4758-326753965
   PubMedGoogle Scholar
• Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol. 2016;25(2):74–85. doi:10.1016/j.suronc.2016.03.00227312032
   PubMed Web of Science ®Google Scholar
• Wang X, Shi L, Deng Y, et al. Inhibition of leucine aminopeptidase 3 suppresses invasion of ovarian cancer cells through down-regulation of fascin and MMP-2/9. Eur J Pharmacol. 2015;768:116–122. doi:10.1016/j.ejphar.2015.10.03926526349
   PubMed Web of Science ®Google Scholar
• He X, Huang Q, Qiu X, et al. LAP3 promotes glioma progression by regulating proliferation, migration and invasion of glioma cells. Int J Biol Macromol. 2015;72:1081–1089. doi:10.1016/j.ijbiomac.2014.10.02125453285
   PubMed Web of Science ®Google Scholar
• Zhang S, Yang X, Shi H, et al. Overexpression of leucine aminopeptidase 3 contributes to malignant development of human esophageal squamous cell carcinoma. J Mol Histol. 2014;45(3):283–292. doi:10.1007/s10735-014-9566-324477662
   PubMed Web of Science ®Google Scholar
• Saiki I, Fujii H, Yoneda J, et al. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer. 1993;54(1):137–143. doi:10.1002/ijc.29105401228097496
   PubMed Web of Science ®Google Scholar
• Fontijn D, Duyndam MC, van Berkel MP, et al. CD13/aminopeptidase N overexpression by basic fibroblast growth factor mediates enhanced invasiveness of 1F6 human melanoma cells. Br J Cancer. 2006;94(11):1627–1636. doi:10.1038/sj.bjc.660315716685268
   PubMed Web of Science ®Google Scholar
• Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000;60(3):722–727.10676659
   PubMed Web of Science ®Google Scholar
• Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood. 2001;97(3):652–659. doi:10.1182/blood.v97.3.65211157481
   PubMed Web of Science ®Google Scholar
• Bhagwat SV, Petrovic N, Okamoto Y, Shapiro LH. The angiogenic regulator CD13/APN is a transcriptional target of ras signaling pathways in endothelial morphogenesis. Blood. 2003;101(5):1818–1826. doi:10.1182/blood-2002-05-142212406907
   PubMed Web of Science ®Google Scholar
• Mahoney KM, Petrovic N, Schacke W, Shapiro LH. CD13/APN transcription is regulated by the proto-oncogene c-maf via an atypical response element. Gene. 2007;403(1–2):178–187. doi:10.1016/j.gene.2007.08.01017897790
   PubMed Web of Science ®Google Scholar
• Miyashita H, Yamazaki T, Akada T, et al. A mouse orthologue of puromycin-insensitive leucyl-specific aminopeptidase is expressed in endothelial cells and plays an important role in angiogenesis. Blood. 2002;99(9):3241–3249. doi:10.1182/blood.v99.9.324111964289
   PubMed Web of Science ®Google Scholar
• Nomura S, Ito T, Yamamoto E, et al. Gene regulation and physiological function of placental leucine aminopeptidase/oxytocinase during pregnancy. Biochim Biophys Acta. 2005;1751(1):19–25. doi:10.1016/j.bbapap.2005.04.00615894523
   PubMed Web of Science ®Google Scholar
• Keller SR. Role of the insulin-regulated aminopeptidase IRAP in insulin action and diabetes. Biol Pharm Bull. 2004;27(6):761–764. doi:10.1248/bpb.27.76115187412
   PubMed Web of Science ®Google Scholar
• Tsujimoto M, Goto Y, Maruyama M, Hattori A. Biochemical and enzymatic properties of the M1 family of aminopeptidases involved in the regulation of blood pressure. Heart Fail Rev. 2008;13(3):285–291. doi:10.1007/s10741-007-9064-817999179
   PubMed Web of Science ®Google Scholar
• Mizutani S, Shibata K, Kikkawa F, et al. Essential role of placental leucine aminopeptidase in gynecologic malignancy. Expert Opin Ther Targets. 2007;11(4):453–461. doi:10.1517/14728222.11.4.45317373876
   PubMed Web of Science ®Google Scholar
• Shibata K, Kikkawa F, Suzuki Y, et al. Expression of placental leucine aminopeptidase is associated with a poor outcome in endometrial endometrioid adenocarcinoma. Oncology. 2004;66(4):288–295. doi:10.1159/00007832915218296
   PubMed Web of Science ®Google Scholar
• Pilar Carrera M, Ramirez-Exposito MJ, Duenas B, et al. Insulin-regulated aminopeptidase/placental leucil aminopeptidase (IRAP/P-lAP) and angiotensin IV-forming activities are modified in serum of rats with breast cancer induced by N-methyl-nitrosourea. Anticancer Res. 2006;26(2A):1011–1014.16619500
   PubMed Web of Science ®Google Scholar
• Boliang W, Zhong Y, Gu B, Cao Y, Lu J, Xiaoxi T. Application of leucine aminopeptidase in the diagnosis of hepatic diseases. J Fourth Mil Med Univ. 2003;24(9):844–845.
   Google Scholar
• Abdel-Hamid NM, Abouzied MM, Nazmy MH, Fawzy MA, Gerges AS. A suggested guiding panel of seromarkers for efficient discrimination between primary and secondary human hepatocarcinoma. Tumour Biol. 2016;37(2):2539–2546. doi:10.1007/s13277-015-4025-726386723
   PubMedGoogle Scholar